|
시장보고서
상품코드
2055159
응고인자 결핍증 시장 : 질환 유형별, 치료법별, 제형별, 투여 경로별, 연령층별, 최종사용자별, 지역별Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography |
||||||
응고인자 결핍증 시장은 2026년에 54억 3,000만 달러로 추정되며, 2033년까지 95억 5,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 8.4%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 54억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.40% | 2033년 시장 규모 예측 : | 95억 5,000만 달러 |
세계 응고인자 결핍증 시장은 광범위한 혈액학 치료제 시장에서 중요한 부분을 차지하고 있으며, 정상적인 지혈에 필수적인 특정 응고인자의 결핍 또는 기능 장애를 특징으로 하는 드물지만 생명을 위협하는 유전성 출혈성 질환을 치료하는 것을 목표로 합니다. 응고인자 결핍증에는 혈우병 A(제VIII인자 결핍증), 혈우병 B(제IX인자 결핍증), 그리고 제I, II, V, VII, X, XI, XIII 인자와 관련된 더 희귀한 결핍증 등 광범위한 질환이 포함되며, 전 세계적으로 총 약 40만 명이 앓고 있습니다.
이러한 질환은 출혈의 장기화, 자연 출혈, 수술 위험 증가 등의 형태로 나타나며, 응고 인자 보충 요법, 예방적 치료, 그리고 새로운 유전자 치료를 통한 평생 관리가 필요합니다. 기술의 발전과 응고 캐스케이드 메커니즘에 대한 이해가 깊어짐에 따라, 시장은 혈장 유래 농축 제제에서 재조합 응고 인자, 그리고 반감기 연장 제품으로 놀라운 진화를 거듭해 왔습니다. 의료 종사자들의 인식 제고, 진단 능력 향상, 환자 등록 제도의 개선, 그리고 개발도상 지역에서의 전문 의료 접근성 확대가 시장 성장에 기여하고 있습니다. 치료의 전망은 비인자 요법, 피하 투여 제제, 유전자 편집 기술 등 혁신적인 접근 방식에 힘입어 지속적으로 변화하고 있으며, 이러한 만성 질환으로 인한 막대한 경제적 부담을 해결하는 동시에 환자의 편의성과 삶의 질을 향상시키고 있습니다.
시장 역학
세계 응고인자 결핍증 시장은 선진국 및 신흥 시장 동향을 좌우하는 상호 연관된 여러 요인의 견인 속에 견조한 성장세를 보이고 있습니다. 주요 시장 성장 요인으로는 진단 기술의 발전과 신생아 선별 검사 프로그램의 확대로 인해 조기 발견 및 치료 시작이 촉진되면서 유전성 출혈성 질환의 유병률이 증가하고 있다는 점을 들 수 있습니다. 생명공학 분야의 기술적 진보는 치료 패러다임에 혁명을 일으키고 있으며, 반감기가 연장된 재조합 인자의 개발로 인해 주사 횟수가 줄어들고 환자의 치료 순응도가 향상되고 있습니다. 한편, 에미시주맙과 같은 새로운 비중재 요법은 억제제를 보유한 환자에게 대체 치료 옵션을 제공합니다. 특히 신흥 경제국에서의 의료비 증가와 더불어, 인식 제고 캠페인 및 환자 지원 활동의 확대에 힘입어 시장 접근성이 높아지면서 첨단 치료법에 대한 수요가 증가하고 있습니다. 규제상의 우대 조치나 신속 승인 절차 등, 희귀질환 연구 개발 및 희귀의약품 개발을 지원하는 정부의 이니셔티브 또한 시장 성장을 더욱 촉진하고 있습니다. 그러나 여전히 시장을 억제하는 큰 요인이 존재하며, 그 주된 원인은 응고 인자 제제나 첨단 치료법의 터무니없이 높은 비용에 있습니다. 이로 인해 자원이 제한된 환경에서의 접근이 제한되고, 의료 제도에 막대한 재정적 부담이 발생하고 있습니다. 중증 A형 혈우병 환자의 약 25-30%에서 중화항체(억제 물질)가 발생함에 따라 치료 전략이 복잡해지고 치료비가 증가하고 있습니다. 개발도상국 의료 종사자들의 인식 부족, 제품 유통을 위한 콜드체인 인프라의 미비, 그리고 각 시장의 복잡한 규제 환경이 추가적인 과제로 대두되고 있습니다. 혈장 유래 제품공급망 혼란과 혈장 부족은 시장의 변동 요인으로 작용하고 있습니다. 그럼에도 불구하고, 기능적 회복과 장기적인 비용 효율성을 약속하는 유전자 치료의 개발 확대에서 큰 기회가 생겨나고 있습니다. 맞춤형 의료에 대한 관심 증가, 원격 환자 모니터링을 위한 원격의료의 통합, 그리고 아시아태평양 및 라틴아메리카 시장의 헬스케어 인프라에 대한 투자 확대는 시장 확장을 위한 큰 성장 잠재력을 보여주고 있습니다.
본 조사의 주요 특징.
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 응고인자 결핍증 시장의 주요 기업 프로파일을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 응고 인자 결핍증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 응고인자 결핍증 시장을 분석하는 데 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 응고인자 결핍증 시장 : 질환 유형별, 2021년-2033년
제5장 세계의 응고인자 결핍증 시장 : 치료 유형별, 2021년-2033년
제6장 세계의 응고인자 결핍증 시장 : 제형별, 2021년-2033년
제7장 세계의 응고인자 결핍증 시장 : 투여 경로별, 2021년-2033년
제8장 세계의 응고인자 결핍증 시장 : 연령층별, 2021년-2033년
제9장 세계의 응고인자 결핍증 시장 : 최종사용자별, 2021년-2033년
제10장 세계의 응고인자 결핍증 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 조사 방법
LSH 26.06.22Coagulation Factor Deficiency Market is estimated to be valued at USD 5.43 Bn in 2026 and is expected to reach USD 9.55 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.43 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.40% | 2033 Value Projection: | USD 9.55 Bn |
The global coagulation factor deficiency market represents a critical segment within the broader hematology therapeutics landscape, addressing rare but life-threatening inherited bleeding disorders characterized by the absence or dysfunction of specific clotting factors essential for normal hemostasis. Coagulation factor deficiencies encompass a spectrum of conditions including hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and rarer deficiencies involving factors I, II, V, VII, X, XI, and XIII, collectively affecting approximately 400,000 individuals worldwide.
These disorders manifest through prolonged bleeding episodes, spontaneous hemorrhages, and increased surgical risks, necessitating lifelong management through factor replacement therapies, prophylactic treatments, and emerging gene therapies. The market has witnessed substantial evolution from plasma-derived concentrates to recombinant factors and extended half-life products, driven by technological advancements and improved understanding of coagulation cascade mechanisms. Rising awareness among healthcare professionals, enhanced diagnostic capabilities, improved patient registries, and expanding access to specialized care in developing regions contribute to market growth. The therapeutic landscape continues to transform with innovative approaches including non-factor therapies, subcutaneous formulations, and gene editing technologies, offering enhanced convenience and improved quality of life for patients while addressing the substantial economic burden associated with these chronic conditions.
Market Dynamics
The global coagulation factor deficiency market demonstrates robust growth dynamics driven by multiple interconnected factors that shape its trajectory across developed and emerging markets. Primary market drivers include the increasing prevalence of inherited bleeding disorders due to improved diagnostic techniques and expanded newborn screening programs, which enhance early detection and treatment initiation. Technological advancements in biotechnology have revolutionized treatment paradigms, with the development of extended half-life recombinant factors reducing injection frequency and improving patient compliance, while novel non-factor therapies like emicizumab provide alternative treatment options for patients with inhibitors. Rising healthcare expenditure, particularly in emerging economies, coupled with growing awareness campaigns and patient advocacy initiatives, expands market accessibility and drives demand for advanced therapeutics. Government initiatives supporting rare disease research and orphan drug development, including regulatory incentives and expedited approval pathways, further stimulate market growth. However, significant market restraints persist, primarily centered around the prohibitive cost of factor concentrates and advanced therapies, which limit accessibility in resource-constrained settings and create substantial financial burden on healthcare systems. The development of neutralizing antibodies (inhibitors) in approximately 25-30% of severe hemophilia A patients complicates treatment strategies and increases therapeutic costs. Limited awareness among healthcare providers in developing regions, inadequate cold chain infrastructure for product distribution, and regulatory complexities across different markets pose additional challenges. Supply chain disruptions and plasma shortages for plasma-derived products create market volatility. Nevertheless, substantial opportunities emerge from expanding gene therapy developments, which promise potential functional cures and long-term cost-effectiveness. Growing focus on personalized medicine approaches, telemedicine integration for remote patient monitoring, and increasing healthcare infrastructure investments in Asia Pacific and Latin American markets present significant growth potential for market expansion.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global coagulation factor deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Baxter International Inc., CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Novo Nordisk A/S, Pfizer Inc., Bayer AG, Sobi (Swedish Orphan Biovitrum), Biogen Inc., Octapharma AG, Sanofi S.A., Amgen Inc., Genentech, Inc., and UCB S.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global coagulation factor deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global coagulation factor deficiency factor.
Market Segmentation
- Disorder Type Insights (Revenue, USD Bn, 2021 - 2033)
- Hemophilia A (Factor VIII Deficiency)
- Hemophilia B (Factor IX Deficiency)
- Hemophilia C (Factor XI Deficiency)
- Von Willebrand Disease
- Type 1-Mild deficiency of von Willebrand factor (VWF)
- Type 2-Abnormal function of VWF
- Rare Factor Deficiencies
- Factor I (Fibrinogen) Deficiency
- Factor II (Prothrombin) Deficiency
- Factor V Deficiency
- Factor VII Deficiency
- Factor X Deficiency
- Factor XIII Deficiency
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Replacement Therapy
- Plasma-derived Coagulation Factors
- Recombinant Coagulation Factors
- Non-replacement Therapy
- Desmopressin (DDAVP)
- Antifibrinolytics
- Anticoagulants
- Gene Therapy
- Adeno-Associated Virus (AAV) Gene Therapy
- Lentivirus Gene Therapy
- Others (Hormonal Therapy)
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Lyophilized Powder for Reconstitution
- Liquid Solution for Injection/Infusion
- Oral Formulations
- Nasal Spray
- Other Viral Vector Suspension
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Intravenous
- Subcutaneous
- Intranasal
- Oral
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Pharmacies
- Hemophilia Treatment Centers
- Homecare Settings
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others (Academic & Research Institutions.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Baxter International Inc.
- CSL Behring
- Grifols S.A.
- Takeda Pharmaceutical Company
- Novo Nordisk A/S
- Pfizer Inc.
- Bayer AG
- Sobi (Swedish Orphan Biovitrum)
- Biogen Inc.
- Octapharma AG
- Sanofi S.A.
- Amgen Inc.
- Genentech, Inc.
- UCB S.A.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Coagulation Factor Deficiency Market, By Disorder Type
- Global Coagulation Factor Deficiency Market, By Treatment Type
- Global Coagulation Factor Deficiency Market, By Dosage Form
- Global Coagulation Factor Deficiency Market, By Route of Administration
- Global Coagulation Factor Deficiency Market, By Age Group
- Global Coagulation Factor Deficiency Market, By End User
- Global Coagulation Factor Deficiency Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hemophilia A (Factor VIII Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hemophilia B (Factor IX Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hemophilia C (Factor XI Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Von Willebrand Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Type 1-Mild deficiency of von Willebrand factor (VWF)
- Type 2-Abnormal function of VWF
- Rare Factor Deficiencies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Factor I (Fibrinogen) Deficiency
- Factor II (Prothrombin) Deficiency
- Factor V Deficiency
- Factor VII Deficiency
- Factor X Deficiency
- Factor XIII Deficiency
5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Plasma-derived Coagulation Factors
- Recombinant Coagulation Factors
- Non-replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Desmopressin (DDAVP)
- Antifibrinolytics
- Anticoagulants
- Desmopressin (DDAVP)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adeno-Associated Virus (AAV) Gene Therapy
- Lentivirus Gene Therapy
- Others (Hormonal Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Lyophilized Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Liquid Solution for Injection/Infusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral Formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Viral Vector Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Coagulation Factor Deficiency Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Coagulation Factor Deficiency Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hemophilia Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Academic & Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Coagulation Factor Deficiency Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grifols S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sobi (Swedish Orphan Biovitrum)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
